tiprankstipranks
Bio-Path Holdings Advances Clinical Pipeline for 2025
Company Announcements

Bio-Path Holdings Advances Clinical Pipeline for 2025

Story Highlights

Stay Ahead of the Market:

Bio-Path Holdings ( (BPTH) ) has issued an announcement.

Bio-Path Holdings announced significant advancements in its clinical development pipeline for 2025, including the exploration of its lead product, prexigebersen, in treating both acute myeloid leukemia (AML) and obesity in Type 2 Diabetes patients. The company is focusing on utilizing molecular biomarkers to enhance patient response rates in its Phase 2 AML trial and is preparing to file an Investigational New Drug application for BP1001-A’s obesity treatment. Concurrently, Bio-Path is progressing with Phase 1/1b trials for BP1001-A and BP1002, aiming to address unmet needs in solid tumors and venetoclax-resistant AML. These developments are poised to potentially improve patient outcomes and expand Bio-Path’s market reach in oncology and metabolic disorder treatments.

More about Bio-Path Holdings

Bio-Path Holdings, Inc. is a biotechnology company specializing in the development of nucleic acid cancer and obesity drugs using its proprietary DNAbilize® liposomal delivery and antisense technology. The company focuses on creating targeted treatments for cancer and obesity-related conditions, including Type 2 Diabetes, through a pipeline of RNAi nanoparticle drugs.

YTD Price Performance: -14.96%

Average Trading Volume: 2,119,436

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: $4.21M

For an in-depth examination of BPTH stock, go to TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App